Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
Abeona Therapeutics (Nasdaq: ABEO) has appointed two new independent members to its Board of Directors: Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD. Dr. Zeiher brings over 20 years of drug development experience, having overseen the approval of 15 new treatments for serious diseases. Dr. Crombez, currently Chief Medical Officer at Ultragenyx Pharmaceutical, offers extensive expertise in clinical development programs for rare genetic disorders.
The appointments come at a important time for Abeona as it focuses on bringing pz-cel to patients with recessive dystrophic epidermolysis bullosa and seeks to advance its pipeline. Both new board members bring diverse drug development expertise that could prove valuable for Abeona's future strategies and growth.
Abeona Therapeutics (Nasdaq: ABEO) ha nominato due nuovi membri indipendenti per il suo Consiglio di Amministrazione: Bernhardt G. Zeiher, MD, FCCP, FACP, e Eric Crombez, MD. Il Dr. Zeiher porta con sé oltre 20 anni di esperienza nello sviluppo di farmaci, avendo supervisionato l'approvazione di 15 nuovi trattamenti per malattie gravi. Il Dr. Crombez, attualmente Chief Medical Officer di Ultragenyx Pharmaceutical, offre una vasta esperienza nei programmi di sviluppo clinico per disturbi genetici rari.
Queste nomine avvengono in un momento importante per Abeona, mentre si concentra sull'introduzione di pz-cel per i pazienti affetti da epidermolisi bollosa distrofica recessiva e cerca di far avanzare il proprio pipeline. Entrambi i nuovi membri del consiglio portano un'esperienza diversificata nello sviluppo di farmaci che potrebbe rivelarsi preziosa per le strategie future e la crescita di Abeona.
Abeona Therapeutics (Nasdaq: ABEO) ha nombrado a dos nuevos miembros independientes para su Junta Directiva: Bernhardt G. Zeiher, MD, FCCP, FACP, y Eric Crombez, MD. El Dr. Zeiher aporta más de 20 años de experiencia en el desarrollo de medicamentos, habiendo supervisado la aprobación de 15 nuevos tratamientos para enfermedades graves. El Dr. Crombez, actualmente Director Médico de Ultragenyx Pharmaceutical, ofrece una amplia experiencia en programas de desarrollo clínico para trastornos genéticos raros.
Estos nombramientos se producen en un momento importante para Abeona, ya que se centra en llevar pz-cel a pacientes con epidermólisis bullosa distrófica recesiva y busca avanzar en su pipeline. Ambos nuevos miembros de la junta aportan una experiencia diversa en el desarrollo de medicamentos que podría resultar valiosa para las estrategias y el crecimiento futuro de Abeona.
Abeona Therapeutics (Nasdaq: ABEO)가 이사회의 두 명의 새로운 독립 이사를 임명했습니다: Bernhardt G. Zeiher, MD, FCCP, FACP와 Eric Crombez, MD. Zeiher 박사는 20년 이상의 약물 개발 경험을 가지고 있으며, 15개의 새로운 중증 질환 치료제가 승인되는 것을 감독했습니다. 현재 Ultragenyx Pharmaceutical의 최고 의학 책임자인 Crombez 박사는 희귀 유전 질환에 대한 임상 개발 프로그램에서의 폭넓은 전문 지식을 제공합니다.
이번 임명은 Abeona가 열성성 외상 피부 취약증 환자에게 pz-cel을 제공하는 데 집중하고 있으며, 파이프라인을 발전시키려는 중요한 시점에 이루어졌습니다. 두 명의 새로운 이사 모두 Abeona의 향후 전략과 성장에 유용할 수 있는 다양한 약물 개발 전문성을 가져옵니다.
Abeona Therapeutics (Nasdaq: ABEO) a nommé deux nouveaux membres indépendants au sein de son Conseil d'Administration : Bernhardt G. Zeiher, MD, FCCP, FACP et Eric Crombez, MD. Le Dr Zeiher apporte plus de 20 ans d'expérience dans le développement de médicaments, ayant supervisé l'approbation de 15 nouveaux traitements pour des maladies graves. Le Dr Crombez, actuellement Directeur Médical chez Ultragenyx Pharmaceutical, offre une vaste expertise dans les programmes de développement clinique pour les troubles génétiques rares.
Ces nominations interviennent à un moment crucial pour Abeona, alors que l'entreprise se concentre sur la mise à disposition de pz-cel pour les patients atteints d'épidermolyse bulleuse dystrophique récessive et cherche à faire avancer son pipeline. Les deux nouveaux membres du conseil apportent une expertise diversifiée dans le développement de médicaments qui pourrait s'avérer précieuse pour les futures stratégies et la croissance d'Abeona.
Abeona Therapeutics (Nasdaq: ABEO) hat zwei neue unabhängige Mitglieder in seinen Vorstand berufen: Bernhardt G. Zeiher, MD, FCCP, FACP und Eric Crombez, MD. Dr. Zeiher bringt über 20 Jahre Erfahrung in der Arzneimittelforschung mit, in denen er die Genehmigung von 15 neuen Behandlungen für schwere Krankheiten beaufsichtigt hat. Dr. Crombez, der derzeit Chief Medical Officer bei Ultragenyx Pharmaceutical ist, bietet umfangreiche Expertise in klinischen Entwicklungsprogrammen für seltene genetische Störungen.
Diese Ernennungen erfolgen zu einem wichtigen Zeitpunkt für Abeona, da das Unternehmen sich darauf konzentriert, pz-cel für Patienten mit rezessiver dystrophischer Epidermolysis bullosa bereitzustellen und seine Pipeline weiterzuentwickeln. Beide neuen Vorstandsmitglieder bringen vielfältige Expertise in der Arzneimittelforschung mit, die sich für Abeonas zukünftige Strategien und Wachstum als wertvoll erweisen könnte.
- Addition of two experienced board members with extensive drug development expertise
- Dr. Zeiher's track record of overseeing 15 new treatment approvals for serious diseases
- Dr. Crombez's expertise in clinical development for rare genetic disorders
- Potential for valuable insights to advance Abeona's pipeline and bring pz-cel to market
- None.
CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders.
Michael Amoroso, Chairman of Abeona’s Board of Directors, said, “We are delighted to welcome both Bernie Zeiher and Eric Crombez to our Board during this important period in Abeona’s history. As recognized and dynamic life sciences leaders, they bring a wealth of diverse drug development expertise to Abeona. We look forward to their valuable insights as we continue to both focus on bringing pz-cel to patients with recessive dystrophic epidermolysis bullosa and as we seek to advance and expand our pipeline.”
Dr. Zeiher spent more than 10 years at Astellas Pharma, holding multiple roles of increasing responsibility in drug development, leading up to his role as CMO, where he led early- and late-stage drug development, medical and regulatory affairs, pharmacovigilance, and quality assurance. Prior to Astellas, Dr. Zeiher held various roles leading drug development at other pharmaceutical companies including Pfizer and Eli Lilly and Company. He also practiced medicine at a tertiary medical center in Indianapolis. Dr. Zeiher currently serves on multiple public company boards, including Entrada Therapeutics and Amylyx Pharmaceuticals, Inc. He previously served on the boards of TransCelerate Biopharma, Biotechnology Innovation Organization and Astellas Global Health Foundation. Dr. Zeiher received a B.S. in biology from the University of Toledo and an MD from Case Western Reserve University School of Medicine. He completed his internal medicine residency and chief residency at University Hospitals of Cleveland and then finished his physician training as a Pulmonary and Critical Care Fellow at University of Iowa Hospitals and Clinics.
Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics in November 2017. As Chief Medical Officer of Ultragenyx, Dr. Crombez is responsible for strategic leadership of the clinical development and translational research programs, and oversees global development functions including Clinical Development, Clinical Operations, BioMetrics, Endpoint Development and Strategy, Regulatory Affairs and Drug Safety/Pharmacovigilance. At Dimension Therapeutics, Dr. Crombez served as Chief Medical Officer and led the clinical development efforts for their gene therapy programs. Dr. Crombez is also an appointed industry representative on the FDA Cellular, Tissue and Gene Therapies Advisory Committee. Before joining industry, he was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Crombez is a board-certified clinical geneticist and completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous cell-based gene therapy currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and results of ongoing testing and other corrective actions being performed in response to the FDA’s identified deficiencies, which could delay the Company’s BLA resubmission; the timing and outcome of the FDA’s review of our resubmission; the FDA’s grant of a Priority Review Voucher upon approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
Who are the new board members appointed by Abeona Therapeutics (ABEO)?
What experience does Dr. Bernhardt Zeiher bring to Abeona Therapeutics (ABEO)?
What is Dr. Eric Crombez's current role outside of Abeona Therapeutics (ABEO)?
What is Abeona Therapeutics (ABEO) currently focusing on in terms of product development?
